Clairity, a breast imaging AI startup, secured $43M to advance its FDA-cleared mammogram risk prediction tool.
Key Details
- 1Clairity, founded in 2020 by radiologist Dr. Constance Lehman, raised $43 million in Series B funding.
- 2Major investors include Ace Global Equity, Santé Ventures, and the Breast Cancer Research Foundation.
- 3The AI tool predicts five-year breast cancer risk from routine mammograms.
- 4Clairity Breast received FDA de novo authorization in May 2024.
- 5The funds will support commercialization and expanding partnerships.
Why It Matters
This funding enables broader access to AI-driven breast cancer risk prediction using standard mammography, potentially improving early detection and risk stratification. Widespread adoption could reshape preventive strategies and workflow in breast imaging practices.
Source
Radiology Business
Related News
•Radiology Business
Private Equity Backs AIRS Medical to Expand MRI AI Globally
TA Associates is investing in AIRS Medical to accelerate its global expansion of AI-powered MRI efficiency solutions.
•AuntMinnie
SIIM Study: LLMs Excel in Numerical Radiology Tasks
At SIIM 2026, LLMs demonstrated high accuracy on radiology-based numerical tasks, particularly in extraction and judgment tests.
•Radiology Business
AI Predicts Breast Cancer Up to Six Years Before Diagnosis
AI technology using mammograms can predict breast cancer risk up to six years in advance.